WPA launches cancer top up policy to fund new drugs

PMI provider WPA has launched a low cost top up policy designed to provide access to the new breed of cancer drugs often denied patients by the NHS.Mycancerdrugs will provide up to £50,000 worth of cancer treatment for a 12 month period, predominantly to pay for so-called wonder drugs, such as Herceptin, Avastin and Tarceva,…

Membership Required

You must be a HM Subscriber to view this content.

Subscribe Now »

Already have an account?